eISSN: 2957-3629 editor@grpublishing.org
All Journals
Submit your article

Global Journal of Medical and Pharmaceutical Sciences

Open Access Peer Review International
Open Access

EPIGENETIC INACTIVATION OF TUMOR SUPPRESSOR GENES- MARKER FOR MONITORING THE EFFECTIVENESS OF THERAPY

DOI https://doi.org/10.55640/gjmps-abcd118
PDF
D.A. Kadirova 1 , N.SH. AVEZOV 1 , A.N. MAKSUDOVA 1 , A.A. IBRAGIMOV 1 ,
4 Institute of Biophysics and Biochemistry at the National University of the Republic of Uzbekistan. 2
4 Institute of Bioorganic Chemistry named after Obid Sodiqov Academy of Sciences of the Republic of Uzbekistan.
4 Tashkent Pharmaceutical Institute.
4 TASHKENT RESEARCH INSTITUTE OF VACCINES AND SERUM.

Abstract

Epigenetic inactivation of tumor suppressor genes caused by hypermethylation of the promoter area is as characteristic of the tumor process as genetic disorders, serving as an alternative mechanism of the function loss by the tumor suppressor genes. An analysis of the promoter area of RARв2 gene-suppressors has been performed in the normal condition and in breast cancer by methyl-sensitive polymerase chain reaction. Methylation of CpG-dinucleotides in the RARв2 gene promoter area was demonstrated. Abnormal methylation of the RARв2 gene promoter area may be used as a marker for early diagnosis and monitoring of the treatment efficacy in patients with the breast cancer. 

Keywords

breast cancer, tumor suppressor, marker, early diagnosis, monitoring of treatment efficacy

References

📄 Baylin S.B., Esteller M., Rountree M.R. Aberrant pattern of DNA methylation, chromatin and gene expression in cancer// Hum. Mol. Genet.2001. V. 10.P. 687-692-696.
📄 Burbee D.C., Forgacs E., Zochbauer-Muller S. Epigenetic inactivation of RASSF1A in lung and breast cancer and malignant phenotype suppression. // Natl. Cancer Inst.2001. V.93. P. 691-699
📄 Chan A.O., Kim S.G., Bedeir A. et al. CpG island methylation in carcinoid and pancreatic endocrine tumors// Oncogene. 2003. V.13. P. 924-934.
📄 Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer// Nat. Rev. Genet. 2002. V. 3. P. 415-428.
📄 Fraga M.F., Esteller M. Hypermethylation of tumor-suppressing gene and diagnostics of oncological disease// Cancer.2009. V.45. P. 234-239.
📄 Lewis C.M., Cler L.R., Bu D.W. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk// Clin. Cancer Res.2005. V. 11(1). P. 166-172.
📄 Cottrell S.E. Molecular diagnostic applications of DNA methylation technology// Clin Biochem. 2004. V. 37. P. 595-604.
📄 Esteller M., Silva J.M., Bonilla F., Lerma E., Bussaglia E., Repasky E.A. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors// J. Natl Cancer Inst.2000. V. 92.P. 564-569.

How to Cite

Kadirova, D., AVEZOV, N., MAKSUDOVA, A., & IBRAGIMOV, A. (2024). EPIGENETIC INACTIVATION OF TUMOR SUPPRESSOR GENES- MARKER FOR MONITORING THE EFFECTIVENESS OF THERAPY. Global Journal of Medical and Pharmaceutical Sciences, 3(03), 14-19. https://doi.org/10.55640/gjmps-abcd118

Most read articles by the same author(s)

1 2 3 4 5 6 > >>